Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Research & Development (2021 - 2025)

Historic Research & Development for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Q3 2025 value amounting to $19.6 million.

  • Arcutis Biotherapeutics' Research & Development rose 52.82% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.1 million, marking a year-over-year decrease of 1707.4%. This contributed to the annual value of $76.4 million for FY2024, which is 3088.85% down from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' Research & Development stood at $19.6 million, which was up 52.82% from $19.5 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Research & Development ranged from a high of $69.7 million in Q3 2022 and a low of $14.5 million during Q4 2024
  • Moreover, its 5-year median value for Research & Development was $25.2 million (2023), whereas its average is $30.1 million.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Research & Development soared by 8779.53% in 2022, and later tumbled by 6237.54% in 2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Research & Development (Quarter) stood at $52.6 million in 2021, then plummeted by 35.54% to $33.9 million in 2022, then fell by 29.82% to $23.8 million in 2023, then tumbled by 39.1% to $14.5 million in 2024, then skyrocketed by 35.39% to $19.6 million in 2025.
  • Its Research & Development was $19.6 million in Q3 2025, compared to $19.5 million in Q2 2025 and $17.5 million in Q1 2025.